Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about LYC: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet. View on Wiki →
| Name | LYC |
| Key Genes/Proteins | AKT, BECN1, MAP1LC3, PINK1, PRKN |
| Related Pathways | autophagy |
| Linked Hypotheses | 10 hypotheses |
Knowledge base pages for this entity
flowchart TD
N0["LYC"]
N1["AKT"]
N0 -->|"inhibits"| N1
N2["autophagy"]
N0 -->|"activates"| N2
N3["Renal Fibrosis"]
N0 -->|"treats"| N3
N4["Mitophagy"]
N0 -->|"activates"| N4
N5["BECN1"]
N0 -->|"contributes to"| N5
N6["MAP1LC3"]
N0 -->|"contributes to"| N6
classDef gene fill:#1a3a2a,stroke:#4caf50,color:#e0e0e0
classDef protein fill:#1a2a3a,stroke:#4fc3f7,color:#e0e0e0
classDef disease fill:#3a1a1a,stroke:#ef5350,color:#e0e0e0
classDef pathway fill:#2a1a3a,stroke:#ce93d8,color:#e0e0e0
classDef mechanism fill:#2a2a1a,stroke:#ffd54f,color:#e0e0e0
classDef drug fill:#1a2a2a,stroke:#26c6da,color:#e0e0e0
classDef cell_type fill:#2a1a2a,stroke:#ab47bc,color:#e0e0e0
classDef phenotype fill:#2a2a1a,stroke:#ffa726,color:#e0e0e0
classDef process fill:#1a2a2a,stroke:#66bb6a,color:#e0e0e0
classDef biological_process fill:#1a2a2a,stroke:#66bb6a,color:#e0e0e0
classDef concept fill:#1a1a2a,stroke:#7986cb,color:#e0e0e0
classDef entity fill:#1a2a3a,stroke:#4fc3f7,color:#e0e0e0
classDef therapeutic fill:#1a2a2a,stroke:#26c6da,color:#e0e0e0
classDef index fill:#1a1a2a,stroke:#7986cb,color:#e0e0e0
class N0 concept
class N1 protein
class N2 pathway
class N3 disease
class N4 process
class N5 gene
class N6 gene| Target | Relation | Type | Str |
|---|---|---|---|
| AKT | inhibits | protein | 0.90 |
| autophagy | activates | pathway | 0.90 |
| Autophagy | activates | process | 0.90 |
| AKT | inhibits | protein | 0.85 |
| Renal Fibrosis | treats | disease | 0.85 |
| PINK1 | upregulates | protein | 0.80 |
| PRKN | upregulates | protein | 0.80 |
| BECN1 | contributes_to | gene | 0.80 |
| MAP1LC3 | contributes_to | gene | 0.80 |
| Mitochondrial Membrane Potential | downregulates | phenotype | 0.75 |
| PINK1 | regulates | gene | 0.70 |
| PRKN | regulates | gene | 0.70 |
| Source | Relation | Type | Str |
|---|---|---|---|
| No incoming edges | |||
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Dual-Phase Medium-Chain Triglyceride Intervention | 0.506 | neurodegeneration | How do astrocyte-neuron metabolic intera |
| Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulat | 0.505 | neurodegeneration | Perivascular spaces and glymphatic clear |
| Glycosaminoglycan Template Disruption Approach | 0.464 | neurodegeneration | Protein aggregation cross-seeding across |
| Glycine-Rich Domain Competitive Inhibition | 0.429 | neurodegeneration | TDP-43 phase separation therapeutics for |
| Glial Glycocalyx Remodeling Therapy | 0.415 | neurodegeneration | 4R-tau strain-specific spreading pattern |
| Metabolic Reprogramming via Microglial Glycolysis Inhibition | 0.385 | neurodegeneration | Synaptic pruning by microglia in early A |
| Pharmacological Enhancement of APOE4 Glycosylation | 0.366 | neurodegeneration | APOE4 structural biology and therapeutic |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-16 | 2 hypotheses Top: 0.552
metabolomics | 2026-04-16 | 0 hypotheses
endocrinology | 2026-04-13 | 2 hypotheses Top: 0.572
neurodegeneration | 2026-04-11 | 0 hypotheses
neurodegeneration | 2026-04-10 | 0 hypotheses
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Vascular Contribution to Alzheimer's Disease — Beyond Amyloid | validation | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Vascular Contributions to Alzheimer Disease and Mixed Pathology | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Blood-Brain Barrier Aging and Neurodegeneration — From Leakage to Neur | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $130,000 |
| Proposed experiment from debate on Perivascular spaces and glymphatic | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
| Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FTD | validation | ALS | 0.400 | 0.50 | human | proposed | $2,730,000 |
| FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Mechanism: Progranulin Loss and TDP-43 Pathology in FTD | validation | ALS | 0.400 | 0.50 | human | proposed | $2,730,000 |
| Environmental Exposure Causal Attribution in ALS — Experiment Design | validation | ALS | 0.400 | 0.50 | human | proposed | $3,000,000 |
| ALS Progression Rate Heterogeneity — mechanism and biomarker predictor | clinical | ALS | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Protein Aggregation Kinetic Validation Results | validation | Neurodegeneration | 0.400 | 0.50 | in_silico | proposed | $120,000 |
| TDP-43 PET Ligand Development for FTD and ALS | clinical | ALS | 0.400 | 0.50 | human | proposed | $6,550,000 |
| FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutation Carriers | validation | ALS | 0.400 | 0.50 | human | proposed | $3,000,000 |
| Frontal and Temporal Lobe Selective Vulnerability in FTD — Mechanisms | validation | Neurodegeneration | 0.400 | 0.50 | human | proposed | $3,000,000 |
| Proposed experiment from debate on TDP-43 undergoes liquid-liquid phas | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Proposed experiment from debate on Astrocytes adopt A1 (neurotoxic) an | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
| Proposed experiment from debate on Microglia activate astrocytes via I | falsification | Neuroinflammation | 0.400 | 0.50 | cell_line | proposed | $80,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Autophagy and ALS: mechanistic insights and therapeutic implications. [PMID:34057020] | Chua JP, De Calbiac H, Kabashi E, Barmad | Autophagy | 2022 | 2 |
| TDP-43 Pathology in Alzheimer's Disease. [PMID:34930382] | Meneses A, Koga S, O'Leary J, Dickson DW | Mol Neurodegener | 2021 | 2 |
| Protein transmission in neurodegenerative disease. [PMID:32203399] | Peng C, Trojanowski JQ, Lee VM | Nat Rev Neurol | 2020 | 2 |
| TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS [PMID:33031745] | Yu CH, Davidson S, Harapas CR, Hilton JB | Cell | 2020 | 2 |
| Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of [PMID:30335591] | Rusmini P, Cortese K, Crippa V, Cristofa | Autophagy | 2019 | 2 |
| Bergenin attenuates traumatic brain injury via inhibition of microglial PFKFB3-d [PMID:41520557] | Sun B, Zhang A, Feng S, Jamali AW, Jia Z | Int Immunopharmacol | 2026 | 1 |
| HK1 and HK2 Beyond Glycolysis: Mitochondrial Interactions and Dual Roles in Meta [PMID:41387352] | Pesce NA, Seminara G, Giarrusso G, Tomas | Adv Biol (Weinh) | 2026 | 1 |
| Glucose Metabolic Reprogramming in Microglia: Implications for Neurodegenerative [PMID:39987285] | Fang M, Zhou Y, He K, Lu Y, Tao F, Huang | Mol Neurobiol | 2025 | 1 |
| Deficiency of Microglial Hv1 Protects Against Lipopolysaccharide-Induced Neuroin [PMID:40911376] | Sun L, Wang X, Guan S, Zhang P, Chen D, | FASEB J | 2025 | 1 |
| The PI3K/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer. [PMID:38904014] | Fontana F, Giannitti G, Marchesi S, Limo | Int J Biol Sci | 2024 | 1 |
| AST-120 alleviates renal ischemia-reperfusion injury by inhibiting HK2-mediated [PMID:39217289] | Zhou J, Zhang J, Xu F, Gao H, Wang L, Zh | Mol Med | 2024 | 1 |
| Endogenous stimuli-responsive separating microneedles to inhibit hypertrophic sc [PMID:38448448] | Yang ZR, Suo H, Fan JW, Lv N, Du K, Ma T | Nat Commun | 2024 | 1 |
| The extracellular matrix component perlecan/HSPG2 regulates radioresistance in p [PMID:39149513] | Samaržija I, Lukiyanchuk V, Lončarić M, | Front Cell Dev Biol | 2024 | 1 |
| NETs induce ferroptosis of endothelial cells in LPS-ALI through SDC-1/HS and dow [PMID:38677244] | Fei Y, Huang X, Ning F, Qian T, Cui J, W | Biomed Pharmacother | 2024 | 1 |
| Hexokinase 2-mediated gene expression via histone lactylation is required for he [PMID:37463576] | Rho H, Terry AR, Chronis C, Hay N | Cell Metab | 2023 | 1 |
| N protein of PEDV plays chess game with host proteins by selective autophagy. [PMID:36861818] | Zhai X, Kong N, Zhang Y, Song Y, Qin W, | Autophagy | 2023 | 1 |
| PIKFYVE inhibition mitigates disease in models of diverse forms of ALS. [PMID:36754049] | Hung ST, Linares GR, Chang WH, Eoh Y, Kr | Cell | 2023 | 1 |
| Genetic regulation of post-translational modification of two distinct proteins. [PMID:35332118] | Landini A, Trbojević-Akmačić I, Navarro | Nat Commun | 2022 | 1 |
| Divergent Golgi trafficking limits B cell-mediated IgG sialylation. [PMID:35726710] | Glendenning LM, Zhou JY, Reynero KM, Cob | J Leukoc Biol | 2022 | 1 |
| APRIL limits atherosclerosis by binding to heparan sulfate proteoglycans. [PMID:34433968] | Tsiantoulas D, Eslami M, Obermayer G, Cl | Nature | 2021 | 1 |